Functional similarity of modified cascade impactor to deposit drug particles on cells

Pulmonary drug delivery is a non-invasive and effective route for local or systemic drug administration. Despite several products in the market, the mechanism of drug absorption from the lungs is not well understood. An in vitro model for aerosol deposition and transport across epithelia that uses particle deposition may be a good predictor of and help understand in vivo drug disposition. The objective of this study was to examine the uptake of HFA fluticasone (Flovent HFA) particles at various stages of the Next Generation Impactor (NGI) by human Calu-3 cell line derived from human bronchial respiratory epithelial cell monolayer. Particles were directly deposited on Calu-3 cells incorporated onto stages 3, 5, and 7 of the NGI at the air-liquid interface (ALI). We modified the NGI apparatus to allow particle deposition directly on cells and determined the in vitro deposition characteristics using modified NGI. Particles of different size ranges showed different in vitro epithelial transport rates. This study highlights the need to develop in vitro test systems to determine the deposition of aerosol particles on cell monolayers by simultaneously considering aerodynamic properties.

肺部药物递送是局部或全身药物给药的一种无创和有效的途径。尽管市场上有几种产品，但对肺部药物吸收的机制尚不清楚。使用粒子沉积的气溶胶沉积和运输的体外模型可能是对体内药物处置的良好预测因子，并有助于了解体内药物处置。这项研究的目的是检查下一代撞击器（NGI）的HFA氟替卡松（Flovent HFA）颗粒的摄取，该颗粒是由人支气管呼吸道呼吸性上皮细胞单层单层衍生而来的人类Calu-3细胞系的摄取。将颗粒直接沉积在空中液体界面（ALI）的NGI的第3、5和7阶段的Calu-3细胞上。我们修改了NGI设备，以直接在细胞上沉积颗粒，并使用改良的NGI确定体外沉积特性。不同尺寸范围的颗粒显示出不同的体外上皮转运率。这项研究强调了开发体外测试系统的需求，以同时考虑空气动力学特性，以确定细胞单层上的气溶胶颗粒的沉积。